ASCO GI 2021 | Phase III study of NUC-1031 for first-line treatment of CCA

Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, provides an update on NuTide:121, an ongoing Phase III study of NUC-1031, a nucleoside analog, and cisplatin vs gemcitabine and cisplatin for first-line treatment of patients with advanced cholangiocarcinoma (CCA). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).